Mechanisms and Role of HLA and non-HLA Alloantibodies

Tinckam, Kathryn; Chandraker, Anil

doi:10.2215/cjn.00270106

Cited by 64 publications

(26 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, their real role in humans is still insufficiently known. 35,36 Dinavahi et al 33 searched for autoantibodies (IgG isotype) against graft-expressed, non-HLA antigens, including B2GPI, and did not find aB2GPI antibodies. No IgA antibodies were included in their analysis.…”

Section: Discussionmentioning

confidence: 99%

Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to β 2-Glycoprotein I

Morales

Martínez-Flores²,

Serrano

et al. 2015

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to β 2-Glycoprotein I

Morales

Martínez-Flores²,

Serrano

et al. 2015

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…5,20 A positive crossmatch before kidney transplantation has been associated with rejection and a poor outcome. 3 Graft rejections after allogeneic hematopoietic SCT have occurred as a relatively rare complication when using myeloablative conditioning.…”

Section: Discussionmentioning

confidence: 99%

“…3,4 Alloantibodies after organ transplantation may be directed against both HLA and non-HLA Ags. 5 The first crossmatch techniques to be introduced used C 0 -dependent cytotoxicity with donor T-and/or B-lymphocytes as target cells allowing detection of donor-reactive HLA class I-and II-specific antibodies. 3 By applying flow cytometry to the crossmatch tests, increased sensitivity with regard to detection of donor-reactive antibodies has been accomplished.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection

Mattsson

Nordlander

Remberger

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

The predictive value of cytotoxic crossmatch analysis before allo-SCT remains unclear. We retrospectively analyzed the clinical impact of cytotoxic T-and B-cell crossmatch testing before allo-SCT between January 2000 and June 2005. Cytotoxic crossmatches were performed in 157 patients receiving stem cells from matched unrelated donors or an HLA-A, -B or -DRB1 allele mismatched graft. Ninety patients are still alive. Eleven patients rejected their grafts. One of 11 patients with rejection was positive in a T-cell crossmatch before allo-SCT and 4 of 11 in B-cell crossmatches. T-cell crossmatches showed a sensitivity of 9% and a specificity of 97% compared with 36 and 86% for B-cell crossmatches. Positive T-and/or B-crossmatch before SCT had no predictive value for survival in this study as compared with patients with a negative crossmatch. In conclusion, the pretransplant cytotoxic T-and/or B-crossmatch is a poor predictor of rejection after allo-SCT.

show abstract

“…New laboratory assays have enabled identification and quantification of antibodies against human leukocyte antigen (HLA) class I and class II antigens and even non-HLA antigens (20). The exact clinical significance of these antibodies is still being elucidated but their role in early and late graft loss is gaining significant traction.…”

Section: Rejectionmentioning

confidence: 99%

The future of cardiac transplantation

Koomalsingh¹,

Kobashigawa²

2018

Ann. Cardiothorac. Surg.

View full text Add to dashboard Cite

The first human-to-human heart transplant was performed 50 years ago in 1967. Heart transplantation has now entered an era of tremendous growth and innovation. The future of heart transplantation is bright with the advent of newer immunosuppressive medications and strategies that may even result in tolerance.Much of this progress in heart transplant medicine is predicated on a better understanding of acute and chronic rejection pathways through basic science studies. The future will also include personalized medicine where genomics and molecular science will dictate customized treatment for optimal outcomes. The introduction of mechanical circulatory support (MCS) devices has changed the landscape for patients with severe heart failure to stabilize the most ill patient and make them better candidates for heart transplant.As ex vivo preservation takes hold, we may witness an expansion of the donor pool through the use of donation after cardiac death (DCD) donors. In addition, further geographical donor heart sharing through ex vivo preservation may further decrease waitlist mortality by enabling longer distance donor hearts to be allocated for the sickest waitlist patient. It is no doubt an exciting time to be involved in the field of heart transplantation. In this perspective, we will summarize the present state of heart transplantation and discuss various innovations that are being pursued.

show abstract

Mechanisms and Role of HLA and non-HLA Alloantibodies

Cited by 64 publications

References 97 publications

Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to β 2-Glycoprotein I

Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to β 2-Glycoprotein I

Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection

The future of cardiac transplantation

Contact Info

Product

Resources

About